Drugs / PLM-102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07549464 | Oct 2026 → Jun 2029 expected | acute myeloid leukemia | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PLM-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07549464 ↗ |
| Route | Oral | “Given by mouth” NCT07549464 ↗ |